Literature DB >> 15988706

Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.

Marie-Hélène Gannagé-Yared1, Rabih R Azar, Mireille Amm-Azar, Simon Khalifé, Myrna Germanos-Haddad, Ramy Neemtallah, Georges Halaby.   

Abstract

BACKGROUND: The effect of statins on insulin resistance is controversial and poorly studied in nondiabetic subjects. In addition, the effect of statins on leptin and adiponectin has never been studied.
METHODS: Forty healthy nondiabetic volunteers (22 men and 18 women) aged 28 to 72 were randomized either to placebo or pravastatin 40 mg daily for a 12-week period. Insulin resistance, assessed using the Quantitative Insulin Sensitivity Check Index (QUICKI), as well as serum leptin and adiponectin levels, was measured at baseline and at the end of therapy.
RESULTS: Pravastatin treatment decreased total cholesterol, low-density lipoprotein cholesterol, and triglycerides levels by 24%, 32%, and 14%, respectively ( P < .05 for all), but did not affect glucose and insulin levels, the (QUICKI) index, and adiponectin and leptin levels. When stratification was performed according to QUICKI index or sex, no significant differences were observed in the prevalues and postvalues of leptin, adiponectin, or QUICKI index in the pravastatin group. Adiponectin, leptin, and QUICKI index were statistically higher in women than in men ( P < .001 for both variables). Adiponectin was negatively correlated with body mass index (BMI; r = -0.39, P < .05) and positively correlated with the QUICKI index ( r = 0.54, P < .001) and with high-density lipoprotein cholesterol ( r = 0.50, P < .01). The relation between adiponectin and QUICKI index remained significant after adjustment for sex and BMI ( P = .005 and P = .007, respectively). Leptin was only related to BMI ( r = 0.57, P < .001) and to sex ( P < .001) with no significant correlations with lipid parameters or QUICKI index. Both sex and BMI are independent predictors of leptin ( P < .001 and P < .001).
CONCLUSION: A 12-week treatment with pravastatin 40 mg/d does not change the QUICKI index and leptin and adiponectin levels in healthy volunteers. In addition, our results emphasize the importance of sex and BMI in the determination of both adiponectin and leptin. Adiponectin was also related to QUICKI index, whereas this relation was not found with leptin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988706     DOI: 10.1016/j.metabol.2005.02.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  22 in total

Review 1.  Alternative macrophage activation and metabolism.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 2.  Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

Authors:  Kwang Kon Koh; Michael J Quon; Robert S Rosenson; Wook-Jin Chung; Seung Hwan Han
Journal:  Int J Cardiol       Date:  2007-07-20       Impact factor: 4.164

3.  Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level.

Authors:  Kuei-Chuan Chan; Hsi-Hsien Chou; Chien-Ning Huang; Ming-Chih Chou
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

4.  Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-07-08       Impact factor: 9.079

Review 5.  Leptin and cardiovascular disease: response to therapeutic interventions.

Authors:  Kwang Kon Koh; Sang Min Park; Michael J Quon
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

6.  Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.

Authors:  N P Tatonetti; J C Denny; S N Murphy; G H Fernald; G Krishnan; V Castro; P Yue; P S Tsao; P S Tsau; I Kohane; D M Roden; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-05-25       Impact factor: 6.875

Review 7.  Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Amirhossein Sahebkar; Renato Giua; Claudio Pedone
Journal:  Br J Clin Pharmacol       Date:  2016-10-04       Impact factor: 4.335

8.  Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.

Authors:  C-H Chu; J-K Lee; H-C Lam; C-C Lu; C-C Sun; M-C Wang; M J Chuang; M-C Wei
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

9.  Role of statins in coronary artery disease.

Authors:  Sang Yup Lim
Journal:  Chonnam Med J       Date:  2013-04-25

10.  Statin use and the risk of cholecystectomy in women.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.